There are a number of treatment choices available to treat patients with breast cancer and diagnostic tests can assist in the decision making, according to Adam M. Brufsky, MD, PhD, co-director of the Comprehensive Breast Cancer Center at University of Pittsburgh.
There are a number of treatment choices available to treat patients with breast cancer and diagnostic tests can assist in the decision making, according to Adam M. Brufsky, MD, PhD, co-director of the Comprehensive Breast Cancer Center at University of Pittsburgh.
Transcript
How do you decide between chemotherapy, endocrine therapy, or targeted therapy for your patients? What role do diagnostic tests play in your treatment decisions?
The way I decide between chemotherapy and endocrine therapy really in early-stage breast cancer is number 1, using the estrogen receptor and number 2 I really think that a lot of use of multi parametric genomic tests, such as MammaPrint, Oncotype, EndoPredict, that sort of thing, to help us make clinical decisions as to whether someone should get chemotherapy or not based on their risk.
In late-stage breast cancer, it also is estrogen receptor positivity. It’s HER2 positivity. And I think that even as people get further along in their clinical course and have gone through multiple therapies a lot us are really starting to incorporate sematic DNA testing on these patients to try to find ESR, estrogen receptor, mutations. Potentially, HER2 tyrosine kinase mutations to help us figure out how to best treat these patients. Although those things are kind of experimental at this point, I think generally what I tend to use is estrogen receptor, HER2, how much disease the patient has, for example, I’ll decide between hormone therapy, receptor base, or HER2-base therapy in chemotherapy.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More